Hologic (HOLX) Stock Forecast & Price Target

$79.00 -0.73 (-0.92%)

(As of 05:54 PM ET)

Hologic - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
4

Buy
8

Based on 12 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, and 8 have given a buy rating for HOLX.

Consensus Price Target

$89.91
13.81% Upside

According to the 12 analysts' twelve-month price targets for Hologic, the average price target is $89.91. The highest price target for HOLX is $95.00, while the lowest price target for HOLX is $82.00. The average price target represents a forecasted upside of 13.81% from the current price of $79.00.

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

HOLX Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$89.91	$87.50	$87.60	$86.58
Forecasted Upside	13.81% Upside	8.25% Upside	8.98% Upside	21.04% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.14% Upside	24,609.58% Upside	6.90% Upside
News Sentiment Rating	Positive News See Recent HOLX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	UBS Group 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$84.00 ➝ $90.00	+12.60%
11/5/2024	Mizuho 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $87.00	+8.85%
11/5/2024	Raymond James 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$93.00 ➝ $95.00	+18.85%
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$86.00 ➝ $89.00	+11.72%
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$92.00 ➝ $94.00	+17.79%
10/15/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+10.27%
❗[Investor Alert] Under-the-Radar Tech (Ad) While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO Click here for all the details about today's open round of investing.
10/8/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$95.00 ➝ $90.00	+12.67%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$78.00 ➝ $82.00	+1.61%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$95.00 ➝ $85.00	+4.35%
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$92.00 ➝ $92.00	+12.81%
5/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+24.48%
2/2/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $82.00	+14.22%
8/1/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$94.00 ➝ $86.00	+8.29%
2/2/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$86.00 ➝ $95.00	+14.76%
1/10/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$75.00 ➝ $80.00	+0.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:33 PM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. reported earnings per share (EPS) of $1.01 for the latest quarter, meeting analysts' expectations, which indicates strong financial performance and stability.
The company achieved a revenue of $987.90 million for the quarter, surpassing analyst estimates of $978.25 million, reflecting effective business operations and demand for its products.
With a market capitalization of $18.42 billion, Hologic, Inc. is positioned as a significant player in the medical equipment sector, which can attract institutional investors.
The stock is currently trading around $81.05, which is close to its 50-day moving average, suggesting a potential for price stability and growth.
Hologic, Inc. has a strong net margin of 19.59% and a return on equity of 20.11%, indicating efficient management and profitability, which are attractive traits for investors.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

The company's PEG ratio of 3.03 suggests that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.
Hologic, Inc. has a debt-to-equity ratio of 0.51, which, while manageable, indicates that the company does carry some debt, potentially increasing financial risk.
Despite a solid performance, the stock has a beta of 0.98, indicating that it moves in line with the market, which may not appeal to investors seeking high-growth opportunities.
Recent analyst ratings show a mix of hold and buy ratings, with some firms lowering their target prices, which may signal uncertainty about future performance.
The company operates in a competitive market for medical equipment, which could impact its market share and profitability in the long term.

HOLX Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $89.91, with a high forecast of $95.00 and a low forecast of $82.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HOLX shares.
: According to analysts, Hologic's stock has a predicted upside of 13.81% based on their 12-month stock forecasts.
: Over the previous 90 days, Hologic's stock had 1 downgrade by analysts.
: Hologic has been rated by research analysts at Citigroup, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Raymond James, Royal Bank of Canada, and UBS Group in the past 90 days.
: Analysts like Hologic less than other "medical" companies. The consensus rating score for Hologic is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HOLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

This page (NASDAQ:HOLX) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hologic (HOLX) Stock Forecast & Price Target